Dysfunction of TNFAIP3/A20 Promotes Innate and Non-Infectious Hyperinflammatory Responses
By
Karel F. A. Van Damme
Pieter Hertens
Dorine Sichien
Katrien Van der Borght
Justine Van Moorleghem
Sofie De Prijck
Alex Klarenbeek
Els Louagie
Inés Lammens
Stijn Vanhee
Christian Vanhove
Pieter De Bleser
Steven Van Laecke
Amélie Dendooven
Hamida Hammad
Lars Vereecke
Dirk Elewaut
Geert van Loo
Bart N. Lambrecht
July 17, 2026
Clinical Scorecard: Dysfunction of TNFAIP3/A20 Promotes Innate and Non-Infectious Hyperinflammatory Responses
At a Glance
Category Detail
Condition TNFAIP3/A20 Dysregulation Key Mechanisms Impaired regulation of NF-κB signaling leading to excessive inflammation. Target Population Patients with TNFAIP3-associated diseases, including autoimmune and autoinflammatory disorders. Care Setting Clinical research and experimental models.
Key Highlights
TNFAIP3 (A20) serves as a crucial brake on inflammation. Mutations or haploinsufficiency of TNFAIP3 are linked to inappropriate inflammation. Systemic inflammation from Tnfaip3 deficiency occurs independently of autoreactive antibodies. The gut microbiome does not significantly contribute to the disease manifestations in models studied. Autoantibodies may be a consequence rather than a cause of disease in TNFAIP3 dysregulation. Guideline-Based Recommendations
Diagnosis
Identify polymorphisms in the TNFAIP3 locus linked to autoimmune and autoinflammatory disorders. Management
Consider therapeutic implications for TNFAIP3-associated diseases based on the dysregulation of inflammation. Monitoring & Follow-up
Monitor for systemic inflammation and associated clinical manifestations in patients with TNFAIP3 mutations. Risks
Increased risk of severe inflammation and related complications in patients with TNFAIP3 haploinsufficiency. Patient & Prescribing Data
Individuals with TNFAIP3-related inflammatory disorders.
Therapeutic strategies may need to focus on modulating inflammation rather than targeting autoantibodies.
Clinical Best Practices
Utilize genetic screening for TNFAIP3 mutations in patients with unexplained inflammatory conditions. Implement a multidisciplinary approach to manage systemic inflammation in affected patients. Related Resources & Content
